Your SlideShare is downloading. ×
EU Medical Devices Directive M5 Amendment 93 42 EEC Regulatory Update - BSI British Standards presentation
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

EU Medical Devices Directive M5 Amendment 93 42 EEC Regulatory Update - BSI British Standards presentation

7,577
views

Published on

BSI British Standards' presentation of EU Medical Devices Directive M5 Amendment 93 42 EEC regulatory updates. …

BSI British Standards' presentation of EU Medical Devices Directive M5 Amendment 93 42 EEC regulatory updates.

Presented at the HKTDC Hong Kong International Medical Devices and Supplies Fair 2009.

By Jan van Lochem, Gert Bos and Suzanne Halliday.
Seminar “Regulatory update on medical devices in Asia and EU”.
It covers the revision of the EU medical device directive, implementation of the revised directive, the key changes, changes to clinical requirements, introduction of technical file sampling, and the impact revision on technical or design dossiers.


1 Comment
3 Likes
Statistics
Notes
  • I appreciate your post. I also wrote that SMS advertising provides a cost effective method of targeting promotions to specific customer profiles. You might want to remind customers of specific events or promotions, but for whatever reasons, SMS allows you to pass information directly to the right customer at very affordable prices and fast delivery.
    iso 9000
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Views
Total Views
7,577
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
209
Comments
1
Likes
3
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • 17
  • Transcript

    • 1. M5 Amendment of EU Directive 93/42/EEC - regulatory update Jan van Lochem – Gert Bos – Suzanne Halliday 5 November 2009 HKTDC Hong Kong International Medical Devices and Supplies Fair 2009 Seminar “Regulatory update on medical devices in Asia and EU” For more information on healthcare standards visit: http://shop.bsigroup.com/healthcarestandards
    • 2. Content
      • 1. Revision of the EU medical device directive
      • 2. Implementation of the revised directive
      • 3. Key changes
      • 4. Changes to clinical requirements
      • 5. Introduction of technical file sampling
      • 6. Impact revision on technical or design dossiers
    • 3. 1. Revision of the EU medical device directive
    • 4. History
      • “The Commission shall, no later than 5 years from the date of implementation…..submit a report .....and if necessary make appropriate proposals” 93/42 Article 11.4
      • It was decided that the review should:
        • Cover all aspects
        • Be open to all stakeholders
    • 5. Main Findings of Report
      • Directives provide appropriate legal framework and, in general, work well
      • Areas needing improvements:
        • Conformity assessment
        • Designation & control NoBos
        • Clinical data & PMS
        • Member State resources devoted to implementation
      • Most areas of improvement could be addressed by guidance
    • 6. 2. Implementation of the revised directive
    • 7. Timescales for Implementing
      • 2007/47/EC - 5th (M5) amendment of 93/42/EEC http://ec.europa.eu/enterprise/medical_devices/revision_mdd_en.htm
      • MS required to transpose ‘M5’ into National Laws by 21 December 2008
        • Manufacturers and NoBo may start to implement
        • Directive fully enforced in all MS by 21 March 2010 Manufacturers and Notified Bodies must be in compliance
    • 8. Q&A around amended MDD
      • Do certificates change after 21 March 2010
        • 2007/47 is amending directive, not stand-alone one
        • Existing certificates remain valid; no need to re-issue them on 21 March 2010
        • No need to refer to M5 or 2007/47 on certificates
      • Do Notified Bodies audit to M5 before March 2010
        • Raise observations / OFIs rather than non-conformities to cover the additional requirements
        • Show M4 or M5 as audit basis in Notified Body documents and reports
    • 9. Q&A around amended MDD
      • Can Manufacturers use Essential Requirement Checklists including M5 requirements now?
        • Yes; but they must agree with their Notified Body which versions of their procedures are “official” up to 21 March 2010
      • Is there a requirement to have had an M5 compliance audit before 21 March 2010?
        • No; except where a change in classification requires a different conformity route or additional review by NB
      • After 21 March 2010 all audits must be to 93/42/EEC as amended by 2007/47/EC ie M5
    • 10. State of play certificate changes
      • EC Certificates DO NOT need updating to refer to 2007/47/EC
      • NO assessment required to 2007/47/EC before March 2010 to maintain EC QA Certificates (Annex II, V & VI)
      • NO requirement to review and update EC Design Dossier Examination Certificates before March 2010
      • NEW certificate needed in some reclassifications
      • Evolving guidance, further clarifications expected before March 2010
    • 11. 3. Key changes
    • 12. Key MDD Changes
      • Software in definition, single use devices defined
      • Classification changes, PPE, MD
      • Alternative labelling (draft directive)
      • Clinical evaluation
      • Single authorized rep
      • Improved communication / Confidentiality
      • Essential requirements
      • Quality system & PMS
      • Techfile sampling
    • 13. Essential requirements
      • ER 6a: - always clinical evaluation
      • ER 7.1: - biophysical modelling introduced
      • ER 7.4: - major rewording combination products
      • ER 7.4: - consultation on changes
      • ER 7.5: - carcinogenic, mutagenic, toxic for reproduction, phthalates (67/548/EEC)
      • ER 12.1a - Validation of software
      • ER 13.3 - Authorized representative
      • ER 13.3 - Single use consistency
      • ER 13.6 - risks re-use IFU, latest revision IFU
    • 14. Impact on QA Assessments - General
      • 2007/47 makes some changes to the assessment under the QA modules, eg:
        • Documentation of control of subcontractors
        • Procedure for clinical evaluation
        • Pro-active post market surveillance
      • BSI already emphasises these points as they are both explicit in ISO 13485 , and active PMS was already identified in ISO 14971 and NB-rec on PMS
    • 15. Impact on QA Assessments - General
      • Surveillance audit focuses more on clinical follow-up data, PMS, update risk management file
      • More audit time expected due to introduction of Technical File sampling class IIa and IIb devices
    • 16. All Annexes Document Retention Times
      • What it Says
        • The manufacturer or his authorised representative must, for a period ending at least five years, and in the case of implantable devices at least 15 years, after the last product has been manufactured, keep (records) at the disposal of the national authorities
      • What it Does
        • Increases document retention time (in line with ISO 13485)
        • Distinguishes implants from other products
        • Appears to be unrelated to product lifetime
    • 17. Confidentiality
      • Not treated as confidential:
        • Name manufacturer / authorized rep
        • Certificate info including issuance, modifications, suspensions, withdrawals
    • 18. 4. Changes to clinical requirements
    • 19. Key MDD Changes – clinical
      • Clearer Definitions (Annex X)
        • Clinical Data – safety / performance data (literature, market information, clinical investigation)
        • Clinical Evaluation – review of any type of clinical data
        • Clinical Investigation – clinical study involving human subjects
        • Clinical Evaluation of Clinical Data is required for CE Marking
      • Alignment with MEDDEV 2.7.1 and ISO 14155
    • 20. Key MDD changes – clinical data
    • 21. Annex X – Clinical Evaluation
      • Clinical evaluation for all medical devices
      • Where demonstration of conformity based on clinical data is not deemed appropriate, compliance to ERs must be justified through risk management output, performance evaluation, bench testing and preclinical evaluation. Reason duly substantiated.
      • For implants and class III medical devices: clinical evaluation unless…….
        • Clinical evaluation in technical file (or full reference)
        • Clinical evaluation and documentation must be actively updated based on PMS data
    • 22. Clinical investigations
      • Data relating to clinical investigation in Europe in European database
      • Any interruption, modification, refusal of clinical investigation in EU member states communicated to other Member States in the EU
    • 23. 5. Introduction of technical file sampling
    • 24. Key MDD changes TF sampling IIa and IIb Devices
      • What it Says
        • For devices in Class IIa the notified body shall assess …… the technical documentation … for at least one representative sample for each device subcategory ….
        • For devices in Class IIb the notified body shall assess ….. The technical documentation … for at least one representative sample for each generic device group …
      • What it Does
        • Sets out different sampling regimes for Class IIa and Class IIb
        • Derived from GMDN terminology (BS EN ISO 15445:2000)
        • GMDN definitions are reproduced in Article 1
    • 25. Key MDD Changes – Definitions
      • ‘device subcategory’ means a set of devices having common areas of intended use or common technology (class IIa)
      • ‘generic device group’ means a set of devices having the same or similar intended uses or commonality of technology allowing them to be classified in a generic manner not reflecting specific characteristics (class IIb) Critical for sampling of IIa and IIb technical documentation
    • 26. GMDN – a method of grouping devices
    • 27. Technical Documentation Sampling by Notified Bodies
      • Incorporated in audit plan Notified Bodies, extra audit time
        • Already a MEDDEV 2.10 “requirement”
      • Adds similar sampling under Annex V and VI
      • Defines sampling regimes
      • NBOG Guidance 2009-4 (July 2009) applicable
    • 28. BSI approach to sampling
      • Sampling regimes will be based on rationale agreed with manufacturer
      • BSI objective is to deliver required increased scrutiny in a pragmatic and practical way
      • Class IIa
        • Based on “subcategories” identified in manufacturer scope on certificate
        • Use of NBOG guidance 2009-3 on product categories
      • Class IIb
        • Manufacturer starts from GMDN generic device group definitions
        • BSI, in agreement with manufacturer, rationalises down to representative samples
    • 29. Class IIa – Device subcategory
    • 30. Latest NBOG Guidance on TF sampling, reduced sampling numbers
      • For Class IIb devices: sample of generic device groups, referenced by different GMDN preferred terms, to following plan:
        • Up to 2 groups: a sample from each group
        • Up to 10 groups: a sample from 3 (was 6) of these groups
        • Up to 20 groups: a sample from 5 (was 7) of these groups
        • Up to 30 groups: from 7 (was 8) groups a sample
        • N > 30 groups: from N/10 + 5 groups a sample
    • 31. Sampling –BSI approach
      • Class IIa devices: a sample of each group over a 5 year period.
      • Class IIb devices: determine sample plan for a 5 year period.
      • The Sampling plan updated periodically, at least each 3 years.
    • 32. Depth of Assessment of Technical Files
      • Not full Design Dossier review, but it will cover “essentials”
      • No differentiation between Class IIa and IIb
      • Guidance from NBOG indicates that assessment of each set of technical documentation should consist of review of:
        • classification
        • validity of essential requirements checklist
        • risk management
        • pre-clinical data (studies in animal models, biocompatibility, nanotechnology etc.)
        • clinical data (Note NoBo review as per MEDDEV 2.7.1)
        • declaration of conformity, and
        • other technical documentation based on risk
    • 33. Sampling conclusions
      • Major new requirement for Annex V: involvement NB in review of technical documentation
      • Sampling regime
      • Depth review based on NBOG guidance
      • NBs need to agree sampling regimes with manufacturers as soon as possible
      • Major new requirement for both NoBo and manufacturers
    • 34. 6. Impact revision on technical or design dossiers
    • 35. 2007/47/EC Impact on Technical Documentation
      • Notified Bodies, Manufacturers - Full Compliance Required by 21 March 2010
        • Transition started December 2008
      • New ER’s & Clinical Evaluation Requirements
      • Proactive Review of Amendments by Manufacturer
        • Impact on Technical Documentation & DoC
        • Confirmation Amendments Have Been Considered and if Appropriate Addressed
        • By Product or Manufacturers’ Full Scope, as Appropriate
    • 36. Design Examination or Type Examination Certificates
      • Manufacturer updates DoC to reference 2007/47/EC amendments when satisfied that product complies
      • NB will review compliance with modified Directive during Design Dossier renewals / changes and audits after 21 March 2010
      • Irrespective manufacturer is responsible for ensuring full compliance with 2007/47/EC amendments from 21 March 2010
    • 37. 2007/47/EC Clarifications on Technical Documentation
      • Annex II Technical Documentation
        • A statement indicating whether or not the device is manufactured utilizing tissues of animal origin as referred to in Commission Directive 2003/32/EC
      • Annex II, V & VI Technical Documentation
        • The solutions adopted as referred to in Annex I Section I (2),
          • the preclinical evaluation,
          • the clinical evaluation referred to in Annex X
      • Annex X
        • Confirm that plan for post market clinical follow-up exists and is acted upon and justification for no post market clinical follow-up is documented
    • 38. Summary
      • March 2010 full compliance required
        • No effect on classification?
        • 5 year sampling plans agreed with Notified Body
        • Labelling checked and updated
        • Devices already on the market
        • Devices in stock
        • Updated technical documentation
        • Update declarations of conformity
    • 39. What is next?
      • In June 2008, EC started recast
      • Significant revision of legal framework proposed
        • Converge on global model
        • Harmonize on national differences, reduce fragmentation
        • Strengthen clinical requirements
        • Harmonization quality and oversight Notified Bodies
        • Adapt to new technologies
        • Involve possible EMEA for high risk devices
      • EC preparing next steps, talking to stakeholders
    • 40. Relevant links
      • Website European Commission (new 28 October 2009):
      • http://ec.europa.eu/enterprise/sectors/medicaldevices/index_en.htm
      • Website NBOG:
      • http://www.nbog.eu/
    • 41.
      • For more information on healthcare standards visit: http://shop.bsigroup.com/healthcarestandards
    • 42. © Copyright The British Standards Institution 2010